High-risk patients showed increased sensitivity to chemotherapeutic agents including Gallibiscoquinazole, Cisplatin, Axitinib, and Zoledronate. The anoikis-based risk model may serve as a useful prognostic tool for ACC. ARGs may contribute to ACC progression and are associated with immune microenvironment features, providing a potential basis for further mechanistic and translational studies.

P2, N=30, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

This study evaluated the structural, electronic, pharmacokinetic, and receptor-binding properties of three bisphosphonate derivatives, alendronate, risedronate, and zoledronate, to investigate their therapeutic relevance in osteoporosis and breast cancer. Network analyses highlighted pathways related to mevalonate metabolism, hormone signaling, angiogenesis, extracellular matrix remodeling, and the RANK/RANKL/OPG axis. These findings support the potential repurposing of bisphosphonates, particularly zoledronate, for breast cancer-associated bone disease.

Herein, we engineered a multifunctional ultrasound (US)-responsive nanomodulator (SPNacs) through the co-assembly of a semiconducting polymer sonosensitizer (PF8DPP) and curcumin (Cur) with a reactive oxygen species (ROS)-cleavable polymer shell containing both bone and neutrophil dual-targeting ligands (alendronate and sialic acid)...Consequently, a synergistic effect was achieved to simultaneously suppressed tumor progression and fostered bone tissue regeneration. Collectively, this study presents a promising therapeutic strategy that addresses both tumor eradication and skeletal repair within metastatic bone lesions.

P4, N=2721, Completed, California Pacific Medical Center Research Institute | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Feb 2026 | Trial primary completion date: Oct 2025 --> Feb 2026

In vivo studies showed that osteoclast-specific rab7 conditional knockout mice exhibited osteopetrotic phenotypes. These findings provide insights into how BPs disrupt osteoclast function by blocking autophagy and suggest that targeting autophagy in osteoclasts could be a potential therapeutic approach for bone-related diseases.

P4, N=300, Completed, Oslo University Hospital HF | Active, not recruiting --> Completed

P4, N=900, Recruiting, Wake Forest University Health Sciences | Trial completion date: Sep 2027 --> Jan 2028 | Trial primary completion date: Sep 2027 --> Jan 2028

P3, N=114, Active, not recruiting, Westmead Hospital Research and Education Network | Not yet recruiting --> Active, not recruiting

This first comprehensive FAERS study identifies key drugs associated with ILI, including interferon β-1a, evolocumab, ofatumumab, interferon β-1b, and zoledronic acid. Clinical monitoring for drug-induced ILI is essential to enhance medication safety.

P1/2, N=30, Not yet recruiting, Assistance Publique Hopitaux De Paris

The patient was treated with vinblastine and prednisolone, along with desmopressin and somatotropin replacement. Zoledronic acid was added for osseous disease...This case highlights an unusual presentation of adult LCH with distal lower-extremity and tarsal bone involvement, as well as hypothalamic-pituitary disease preceding osseous diagnosis by two years. It underscores the importance of considering LCH in adults with unexplained multifocal lytic bone lesions and endocrine dysfunction, and it demonstrates that durable disease control can be achieved with systemic therapy.